Diagnostic support you can count on.

Because we know every woman counts on you.


Your dedicated partner in women’s health diagnostics.

For over 20 years, Hologic Women’s Health Diagnostics has championed women and their health by providing essential testing for common cervical, sexual and vaginal issues. Knowing that women’s health depends on your decisions, we support you by investing in advancing care standards, access to testing and market-leading diagnostics.


Essential testing

Our market leading, FDA-approved/FDA-cleared molecular diagnostics and cytology tests ensure you have relevant, accurate, and reliable results to inform your decisions.


Optimal experience

We are invested in simplifying testing to provide the best possible experience for you and your patients across the continuum of care.


Partner in advocacy

As your specialized partner we support you in navigating current policies and guidelines as well as advocate with you for advances in care standards.

Invested in improving women’s health

Cervical screening

  • Studies show 1 in 5 women with cervical cancer were missed by screening with HPV-Alone.1*
  • Screening with Pap + HPV (Co-testing) identified 70% of the cancers missed by HPV-Alone.2*
  • 95% of cervical cancers were detected by testing with Pap + HPV together (Co-testing).2-3

Universal screening

  • Targets all women ages 15-24 regardless of their reported sexual activity.
  • Detects the care opportunities missed by risk-based screening.
  • Along with reducing STI prevalence and infertility, universal screening reduces costs for healthcare organizations.4

Sexually transmitted infections (STIs)

  • 1 in 5 people in the US have an STI.5
  • Patients can present similar symptoms for multiple STIs that require distinct treatment, creating a challenge for diagnosis.
  • Untreated STIs can lead to serious health concerns for women, including pelvic inflammatory disease, ectopic pregnancy, and infertility.6


  • Vaginitis is the leading reason for OBGYN visits.7,8
  • Overlapping symptoms and mixed-infections make clinical diagnosis a challenge.9
  • Traditional methodologies lack detection accuracy, further complicating diagnosis.9

Market leading diagnostics

We offer a broad range of market-leading molecular diagnostics and cytology products for women’s cervical, sexual, and vaginal testing. Our nucleic acid amplification tests (NAATs) demonstrate excellent sensitivity and specificity across a wide variety of disease conditions, while our collection devices yield multiple test results from a single patient sample. Overall, our clinical differentiation guarantees both accuracy and simplicity of use.


Staying current on guidelines is crucial to providing the best care for your patients. As your partner in women’s health, we’ve curated key resources to help inform your testing practices.

Vaginitis, STIs and Universal screening

Cervical cancer screening

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?

*A positive HPV screening result may lead to further evaluation with cytology and/or colposcopy.

1. Kaufman H, et al. Contributions of Liquid-based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074 (Study included ThinPrep Pap test, ThinPrep imaging, SurePath Pap test, SurePath imaging, Aptima HPV and Hybrid Capture 2. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/ cncy.21544 (Study included ThinPrep, SurePath and Hybrid Capture 2 assay. 3. Austin RM, et al. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV co-testing. Am J Clin Pathol.2018;150(5):385-392. doi: 10.1093/ajcp/aqy114 (Study included the ThinPrep® Pap test, ThinPrep imaging, digene HPV, Cervista HPV and Aptima HPV.) 4. Owusu-Edusei K, et al. Cost-Effectiveness of Opt-Out